13F Holdings
中文EN

BIAF bioAffinity Technologies, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%

Returns

ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.16M$9.36M$2.53M$6.90M—
Cost of revenue———$467—
Gross profit———$4,336—
R&D expense$1.38M$1.46M$1.47M$1.38M$1.01M
SG&A expense$9.91M$9.94M$6.79M$2.48M$1.07M
Operating income-$10.57M-$8.95M-$7.97M-$4.01M-$2.21M
Interest expense$44,372$92,475$37,125$2.53M$1.00M
Pretax income-$14.87M-$9.03M-$7.92M-$8.15M-$6.32M
Income tax$44,042$11,650$20,993$2,459$1,950
Net income-$14.91M-$9.04M-$7.94M-$8.15M-$6.33M
EBITDA-$10.07M-$8.35M-$7.72M-$4.00M-$2.20M
EPS (basic)-8.66-22.50-0.91-1.81-2.36
EPS (diluted)-8.66-22.50-0.91-1.81—
Weighted avg. shares (diluted)1.72M404,1678.75M4.50M—
Balance sheet
Cash & equivalents$6.45M$1.11M$2.82M$11.41M$1.36M
Receivables———$10,489—
Inventory$53,548$27,608$18,484$5,540—
Current assets$7.57M$2.70M$3.97M$11.96M$1.44M
PP&E, net$265,593$375,385$458,633$214,438$4,633
Goodwill$1.40M$1.40M$1.40M——
Intangibles$716,806$775,139$833,472——
Total assets$10.96M$6.51M$8.22M$12.18M$1.45M
Current liabilities$2.91M$3.10M$2.25M$1.14M$13.04M
Total liabilities$3.68M$3.91M$3.37M$1.14M$13.20M
Shareholders' equity$7.28M$2.60M$4.86M$11.04M-$15.79M
Shares outstanding299,826519,1589.39M8.38M2.68M
Cash flow statement
Operating cash flow-$9.33M-$7.26M-$6.04M-$4.07M-$2.05M
Capital expenditure$60,568$79,083$22,902$219,987—
Free cash flow-$9.39M-$7.34M-$6.06M-$4.29M—
Investing cash flow-$60,568-$79,083-$2.21M-$219,987—
Financing cash flow$14.73M$5.63M-$344,984$14.34M$3.33M
Depreciation & amortization$504,836$605,637$249,592$10,182$4,817
Stock-based compensation$671,474$989,681$748,823$248,592$43,012

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.